Anonymous
Not logged in
Talk
Contributions
Create account
Log in
Search
Editing
AIM ImmunoTech
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Namespaces
Page
Discussion
More
More
Page actions
Read
Edit
Edit source
History
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
[[File:Hemispherx logo.gif|right|250px]] '''AIM ImmunoTech''', formerly known as '''Hemispherx Biopharma,'''<ref name="name">{{Cite web | url = http://www.globenewswire.com/news-release/2019/08/23/1905934/0/en/Hemispherx-Biopharma-Inc-Changes-Name-to-AIM-ImmunoTech-Inc-Reflecting-Ampligen-s-Immuno-Modulation-Progress-in-Ongoing-Oncology-Clinical-Trials-and-ME-CFS.html | title = Changes Name to AIM ImmunoTech Inc. Reflecting Ampligen’s® Immuno Modulation Progress in Ongoing Oncology Clinical Trials and ME/CFS | last = Hemispherx Biopharma Inc | first = | date = 2019-08-23 | website = GlobeNewswire News Room | access-date = 2019-09-26}}</ref> is a small American pharmaceutical company that produces the drug [[Ampligen]] (rintatolimod). AIM ImmunoTech's corporate headquarters are in Ocala, Florida (formerly in Philadelphia, PA) and the main manufacturing and research facility is in New Brunswick, NJ.<ref name="contact">{{Cite web | url = https://aimimmuno.com/contact/ | title = Contact | last = AIM ImmunoTech | first = | website = AIM ImmunoTech Inc.|language=en-US | access-date = 2022-06-17}}</ref> In addition to Ampligen® (rintatolimod), AIM ImmunoTech produces Alferon N Injection® and Alferon® LDO (Low Dose Oral). To date, only Alferon N Injection® has [[Food and Drug Administration|FDA]] approval. Ampligen® and Alferon® LDO are not FDA-approved and are considered experimental.<ref name="home">{{Cite web | url = https://aimimmuno.com/ | title = Home | last = ImmunoTech | first = | website = AIM ImmunoTech Inc.|language=en-US | access-date = 2019-09-26}}</ref> Ampligen is available to a small number of patients under the [[compassionate use|expanded access]] program.<ref name="AMP-511">{{Cite web | url = https://finance.yahoo.com/news/hemispherx-biopharma-inc-announces-advancement-133000883.html | title = Hemispherx Biopharma Inc. Announces Advancement in Expanded Access Program for Ampligen in the Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome | last = | first = | author-link = | date = Jan 2, 2019 | website = Yahoo Finance| publisher = GlobeNewswire|language=en-US|archive-url=|archive-date= | access-date = 2019-02-10}}</ref> In Jan 2018, [[Thomas Equels]], chief executive officer of AIM ImmunoTech, released a letter instructing every Hemispherx employee to watch the documentary [[Unrest]] and urged their affiliates and stockholders to do the same, in an effort to share information about [[ME/CFS]], one of the primary disease targets for their drug Ampligen.<ref name="Unrest-memo">https://sec.report/Document/0001493152-18-000820/ex99-1.htm</ref> ==Change in leadership== In Feb 2016, Dr. [[William Carter]], then Chairman and CEO, was terminated by the board of directors of Hermispherx Biopharma, now AIM ImmunoTech, who cited that part of the reason was a strong financial austerity plan. William M. Mitchell, M.D., Ph.D. was promoted in house as his replacement.<ref>{{Cite news |url =https://www.bizjournals.com/philadelphia/news/2016/02/19/philly-biotech-hemispherx-fires-ceo-william-carter.html | title = Philadelphia biotech firm fires longtime chairman & CEO | last = George | first = John | date = Feb 19, 2016|work=Philadelphia Business Journal | access-date = 2019-09-26| archive-url = | archive-date = |url-status = | quote=}}</ref> In June 2016, the law suit was resolved between Dr. Carter and Hemispherx, now AIM ImmunoTech, regarding the wrongful termination claim. As part of the settlement, the intellectual property rights, including the patent for Ampligen and Alferon, are irrevocably assigned to to AIM ImmunoTech.<ref>{{Cite news |url =https://www.bizjournals.com/philadelphia/news/2016/06/07/hemispherx-gets-ip-rights-from-fired-ceo-carter.html | title = Hemispherx gets IP rights from the CEO it fired | last = George | first = John | date = Jun 7, 2016|work=Philadelphia Business Journal | access-date = 2019-09-26| archive-url = | archive-date = |url-status = | quote=}}</ref> ==Management== *[[Thomas Equels|Thomas K. Equels]], M.S., J.D. - Chief Executive Officer, President *Robert Dickey IV, CPA - Chief Financial Officer, Executive Vice Chairman *Peter W. Rodino III, J.D. - Chief Operating Officer, Secretary, General Counsel, Executive Director for Governmental Relations *[[David Strayer|David R. Strayer]], M.D. - Chief Scientific & Medical Officer ==Board of directors== *[[William Mitchell|William M. Mitchell]], M.D., Ph.D. - Chairman of the Board *Thomas K. Equels, M.S., J.D. - Executive Vice Chairman of Board *Stewart Appelrouth, MBA. - Director<ref name="contact"/> ==Marketing history== {{main article| page_name=Marketing History of Ampligen}} ==Online presence== *[https://aimimmuno.com/ Website] *[https://www.linkedin.com/company/aimimmuno LinkedIn] *[https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000946644 SEC filings - Hemispherx Biompharma] ==Talks and interviews== *2016, [https://www.youtube.com/watch?v=RVwAHIjNkb4&feature=youtu.be Small Cap Nation - ME/CFS (Updated)] ([[Thomas Equels]]) ==See also== *[[Ampligen]] *[[David Strayer]] *[[Marketing History of Ampligen]] *[[Thomas Equels]] *[[William Carter]] *[[William Mitchell]] ==Learn more== *[https://en.wikipedia.org/wiki/Hemispherx_Biopharma Wikipedia - Hemispherx Biopharma] *[https://en.wikipedia.org/wiki/Rintatolimod Wikipedia - Rintatolimod] *http://simmaronresearch.com/2016/05/hemispherx-ampligen-approval-chronic-fatigue-syndrome-top-priority/ *2014, [http://investorshub.advfn.com/boards/read_msg.aspx?message_id=96215994 Investor's post about HEB's rocky history] *2016, [https://www.benzinga.com/general/biotech/16/12/8851721/hemispherx-biopharma-ceo-explains-chronic-fatigue-syndrome-and-how-the Hemispherx BioPharma CEO Explains Chronic Fatigue Syndrome And How The Company Is Treating It]<ref>{{citation | last = Hasse | first = Javier | date = Dec 30, 2016 | title = Hemispherx BioPharma CEO Explains Chronic Fatigue Syndrome And How The Company Is Treating It|url= https://www.benzinga.com/general/biotech/16/12/8851721/hemispherx-biopharma-ceo-explains-chronic-fatigue-syndrome-and-how-the|newspaper= Benzinga|location= Detroit Michigan|access-date= }}</ref> *2016, [http://cdn2.hubspot.net/hubfs/150154/docs/Hemispherx-Executive-Informational-Overview-11-27-16.pdf?__hssc=75734090.1.1482434979170&__hstc=75734090.d484bcfed76166643c7e8f36a0c76637.1482434979170.1482434979170.1482434979170.1&__hsfp=4187238277&hsCtaTracking=afde00a7-b0f3-44d3-b072-5febf480affb%7Cb8ddd437-9009-4bb9-a8fe-65a376fff33f Executive Informational Overview by Crystal Research Associates]<ref name="Crystal, 2016" /> *2016, [http://www.streetinsider.com/Corporate+News/Hemispherx+Biopharma+%28HEB%29+Comments+on+Recent+Meeting+with+NIH+for+MECFS+Research+Advancement/11408291.html Hemispherx Biopharma (HEB) Comments on Recent Meeting with NIH for ME/CFS Research Advancement] (see also [[NIH Post-Infectious ME/CFS Study]]) *2016, [http://www.cortjohnson.org/forums/threads/ampligen-co-inventor-head-of-hemispherx-biopharma-fired-implications-for-me-cfs-drug-unclear.3729/ Ampligen Co-Inventor / Head of Hemispherx Biopharma Fired: Implications for ME/CFS Drug Unclear] ==References== <references> <ref name="Crystal, 2016">{{citation | author= Crystal Research Associates | title = Hemispherx Biopharma, Inc. | type = Executive Informational Overview | date = Nov 27, 2016 | url = http://cdn2.hubspot.net/hubfs/150154/docs/Hemispherx-Executive-Informational-Overview-11-27-16.pdf?__hssc=75734090.1.1482434979170&__hstc=75734090.d484bcfed76166643c7e8f36a0c76637.1482434979170.1482434979170.1482434979170.1&__hsfp=4187238277&hsCtaTracking=afde00a7-b0f3-44d3-b072-5febf480affb%7Cb8ddd437-9009-4bb9-a8fe-65a376fff33f }}</ref> </references> [[Category:Pharmaceutical companies]]
Summary:
Please make sure your edits are consistent with
MEpedia's guidelines
.
By saving changes, you agree to the
Terms of use
, and you irrevocably agree to release your contribution under the
CC BY-SA 3.0 License
and the
GFDL
. You agree that a hyperlink or URL is sufficient attribution under the Creative Commons license.
Cancel
Editing help
(opens in new window)
Templates used on this page:
Template:Citation
(
edit
)
Template:Cite news
(
edit
)
Template:Cite web
(
edit
)
Template:Colon
(
edit
)
Template:GetFallback
(
edit
)
Template:LangSwitch
(
edit
)
Template:Main article
(
edit
)
Template:Uselang
(
edit
)
Module:Citation/CS1
(
edit
)
Module:Citation/CS1/COinS
(
edit
)
Module:Citation/CS1/Configuration
(
edit
)
Module:Citation/CS1/Date validation
(
edit
)
Module:Citation/CS1/Identifiers
(
edit
)
Module:Citation/CS1/Utilities
(
edit
)
Module:Citation/CS1/Whitelist
(
edit
)
Module:No globals
(
edit
)
Navigation
Navigation
Skip to content
Main page
Browse
Become an editor
Random page
Popular pages
Abbreviations
Glossary
About MEpedia
Links for editors
Contents
Guidelines
Recent changes
Pages in need
Search
Help
Wiki tools
Wiki tools
Special pages
Page tools
Page tools
User page tools
More
What links here
Related changes
Page information
Page logs